Tirzepatide

Tirzepatide is a peptide developed by Eli Lilly that activates receptors for two incretin hormones, GLP-1 and GIP. It has been investigated for type 2 diabetes and obesity, with additional interest in cardiovascular outcomes.

GLP-1 and GIP participate in communication between nutrient intake and metabolic responses. Their receptors are relevant to glucose-dependent insulin secretion, while GLP-1 signaling also contributes to appetite and fullness.

Tirzepatide engages both the GLP-1 receptor and the GIP receptor, providing a basis for studying combined incretin signaling. Mechanistic investigations examine effects on glucose regulation, appetite-related signaling, and energy intake, although the supplied notes do not establish the separate contribution of each receptor pathway.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 04 · Clinical evidence

Controlled clinical research supports specific, narrowly defined conclusions.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents tirzepatide as a dual-incretin peptide associated with diabetes care and obesity research. It attributes potential changes in body weight and metabolic regulation to its receptor activity and mentions possible cardiovascular advantages. The guide also discusses gastrointestinal adverse effects and several less common safety concerns, but the extracted material supplies no supporting citations.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The supplied notes do not establish the magnitude, durability, or population-specific relevance of the reported outcomes. They also do not distinguish cardiovascular hypotheses from demonstrated clinical outcomes or adequately contextualize the listed safety risks.

The guide lists nausea, vomiting, diarrhea, and abdominal bloating, alongside concerns about pancreatic inflammation, gallbladder disorders, altered glucose levels, and thyroid tumors observed in animals. Safety data are limited in the supplied material, particularly regarding risk frequency, human relevance of animal findings, and the implications of prior thyroid, pancreatic, gastrointestinal, or kidney conditions. This summary is not medical advice; individualized risk assessment requires a qualified clinician.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Tirzepatide for weight loss and metabolic regulation”
• “Tirzepatide clinical trials in Type 2 diabetes management”
• “Tirzepatide dual agonist therapy for obesity and”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN